Biomedical start - up AesculaTech , part of bio Combinator ’s latest cohort , has developed a material which solidifies at body temperature , potentially offering a drug delivery system that is simple for patients to survive long - term . The Californian pharmaceutical said its material is preparing human trials for treating dry mouth syndrome , in anticipation of gaining regulatory approval by the pharmaceutical Food and Drug Administration . If successful , it could commercialise a once - a - year treatment for the syndrome which affects around 20 million people in the US by 2019 .
Biomedical start-up AesculaTech, part of Y Combinator’s latest cohort, has developed a material which solidifies at body temperature, potentially offering a drug delivery system that is simple for patients to use long-term. The Californian firm said its material is preparing human trials for treating dry eye syndrome, in anticipation of gaining regulatory approval by the US Food and Drug Administration. If successful, it could commercialise a once-a-year treatment for the syndrome which affects around 20 million people in the US by 2019.